109 related articles for article (PubMed ID: 10647226)
1. Clinicopathological features and management of Pakistani patients with multiple myeloma.
Shaheen H; Ghanghroo I; Malik I
J Pak Med Assoc; 1999 Oct; 49(10):233-7. PubMed ID: 10647226
[TBL] [Abstract][Full Text] [Related]
2. Factors affecting outcome of patients with multiple myeloma.
Basit A; Siddiqui N; Hameed A; Muzaffar N; Athar S
J Ayub Med Coll Abbottabad; 2014; 26(3):376-9. PubMed ID: 25671952
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma--presenting as acute kidney injury.
Prakash J; Niwas SS; Parekh A; Vohra R; Wani IA; Sharma N; Usha
J Assoc Physicians India; 2009 Jan; 57():23-6. PubMed ID: 19753754
[TBL] [Abstract][Full Text] [Related]
4. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
5. Survival in multiple myeloma in Kerala.
Nair MK; Varghese C; Krishnan E; Sankaranarayanan R; Nair B
Natl Med J India; 1993; 6(1):7-10. PubMed ID: 8453369
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression.
Mateos MV; Hernández JM; Hernández MT; Gutiérrez NC; Palomera L; Fuertes M; Garcia-Sanchez P; Lahuerta JJ; de la Rubia J; Terol MJ; Sureda A; Bargay J; Ribas P; Alegre A; de Arriba F; Oriol A; Carrera D; García-Laraña J; García-Sanz R; Bladé J; Prósper F; Mateo G; Esseltine DL; van de Velde H; San Miguel JF
Haematologica; 2008 Apr; 93(4):560-5. PubMed ID: 18322252
[TBL] [Abstract][Full Text] [Related]
7. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
[TBL] [Abstract][Full Text] [Related]
8. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
9. The clinicopathological spectrum of renal amyloidosis.
Hsu JY; Shu KH; Chan LP; Lu YS; Cheng CH; Sheu SS; Lian JD
Zhonghua Yi Xue Za Zhi (Taipei); 1994 Oct; 54(4):230-9. PubMed ID: 7982133
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis and therapy of multiple myeloma: current aspects].
Betticher DC; Cerny T; Fey MF
Schweiz Med Wochenschr; 1995 Mar; 125(11):541-51. PubMed ID: 7899848
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma: a ten year study of survival and therapy in a developing nation.
Omoti CE; Omuemu CE
J Pak Med Assoc; 2007 Jul; 57(7):341-4. PubMed ID: 17867255
[TBL] [Abstract][Full Text] [Related]
12. IgD multiple myeloma--a clinical profile and outcome with chemotherapy and autologous stem cell transplantation.
Wechalekar A; Amato D; Chen C; Keith Stewart A; Reece D
Ann Hematol; 2005 Feb; 84(2):115-7. PubMed ID: 15503021
[TBL] [Abstract][Full Text] [Related]
13. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
14. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
15. Systemic immunoglobulin light-chain amyloidosis (AL) in Mexico: a single institution, 30-year experience.
Hernández-Reyes J; Galo-Hooker E; Ruiz-Delgado GJ; Ruiz-Argüelles GJ
Rev Invest Clin; 2012; 64(6 Pt 2):604-8. PubMed ID: 23593777
[TBL] [Abstract][Full Text] [Related]
16. Multiple Myeloma: a Retrospective Analysis of 61 Patients from a Tertiary Care Center.
Sultan S; Irfan SM; Parveen S; Ali H; Basharat M
Asian Pac J Cancer Prev; 2016; 17(4):1833-5. PubMed ID: 27221861
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma after kidney transplantation.
Safadi S; Dispenzieri A; Amer H; Gertz MA; Rajkumar SV; Hayman SR; Lacy MQ; Leung N
Clin Transplant; 2015 Jan; 29(1):76-84. PubMed ID: 25377159
[TBL] [Abstract][Full Text] [Related]
18. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
19. [Polychemotherapy in multiple myeloma. The COMPA protocol].
Vázquez-Villegas V; Delgado Lamas JL; Romero-García F; Rodríguez-Carrillo J; Medina-Ruiz F
Rev Invest Clin; 1989; 41(4):345-50. PubMed ID: 2698501
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up after high-dose therapy for high-risk multiple myeloma.
Barlogie B; Jagannath S; Naucke S; Mattox S; Bracy D; Crowley J; Tricot G; Alexanian R
Bone Marrow Transplant; 1998 Jun; 21(11):1101-7. PubMed ID: 9645572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
